Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 15, 2025
Emerging Company Profile
Mursla: Using extracellular vesicles to detect cancer
Led by former banker Pierre Arsène, the start-up’s first goal is surveillance of cirrhosis patients at risk of liver cancer
BioCentury | Feb 17, 2024
Discovery & Translation
Science spotlight: a germinal center B cell-activating adjuvant, peptide-conjugated CARs and more
BioCentury’s roundup of translational innovations
BioCentury | Feb 5, 2022
Discovery & Translation
Wave’s oligos enhance tissue exposure; plus Rosenberg, Disney and more
BioCentury’s roundup of translational news
BioCentury | Jul 2, 2021
Distillery Therapeutics
A CD81-targeting mAb for solid tumors
DISEASE CATEGORY: Cancer
INDICATION: Breast cancer; lung cancer A mAb targeting the tetraspanin CD81 could treat breast and lung cancers. In human triple-negative breast cancer (TNBC) and lung
INDICATION: Breast cancer; lung cancer A mAb targeting the tetraspanin CD81 could treat breast and lung cancers. In human triple-negative breast cancer (TNBC) and lung
Items per page:
1 - 10 of 13